|
Novel ASO therapeutic targeting CCDC146, a newly identified driver of motor neuron degeneration in ALS
Demonstrated efficacy across both sporadic and familial ALS models, supporting broad patient applicability
Improves motor function, neuronal survival, and lifespan in preclinical ALS models
Abstract
USC researchers have developed a targeted antisense...
|
|
ASOs which target KCTD20 can help reduce neurodegeneration.
Selective and targeted treatment, offering durable neuroprotection and clearance of toxic proteins.
Can be used to treat neurodegeneration, FTD, ALS with multiple genetic backgrounds.
Abstract
Glutamate excitotoxicity drives neurodegeneration in ALS and FTD, yet current treatments offer...
|